Association of cancer with comorbid inflammatory conditions and treatment in patients with Lynch syndrome

Table 5 Details of exposure for each patient with type of cancer and age at diagnosis of cancer

Disease	Genetic Diagnosis	Medication	Duration /mo	Dose/mg	Cancer type and stage	Age at diagnosis of cancer
Ulcerative colitis	PMS2	Ustekinumab,	12		Colon II	19
		Golimumab	6
		Vedolizumab	24
Crohn’s disease	MLH1	6MP	24	50	Colon I	57
Crohn’s disease	PMS2	Adalimumab	18		Colon III	17
		Golimumab	6
		Vedolizumab	12
Sarcoidosis	MLH1	MTX	60	15	Renal I	49
Rheumatoid arthritis	LLS	Etanercept	120		Breast I, Colon IV	76
		Tofacitinib	9
		MTX	35	15
		Azathioprine	72	50
Rheumatoid arthritis	MSH2	MTX	4	20	Colon II	51
		Rituximab	72
Psoriatic arthritis	MSI-H	Adalimumab	36		Colon III	44
		Ustekinumab	10
		MTX	36	15
Dermatomyositis	MSH2	MTX	12	15	NA	NA
Rheumatoid arthritis	MSI-H	MTX	120	10	NA	NA

MSI-H: High microsatellite instability; MTX: Methotrexate; 6MP: 6-mercaptopurine, NA: Not applicable (no cancer seen during duration of the study).